Mutual funds have significantly reduced their technology sector exposure to an eight-year low, driven by concerns over AI disruption, slowi...

Ipca Labs (IPCA) Q1 EBITDA of Rs 3.9 bn was in line with our estimate. Management guidance of 9% revenue growth (excluding Unichem) was bel...

Ipca Laboratories' stock price traded within a range around the Rs 1,360 level during April and May. However, it subsequently trended downw...

Shares of Indian pharmaceutical company, Ipca Laboratories, fell by 3% after the US Food and Drug Administration (USFDA) issued a Form 483 ...

Ipca Laboratories has agreed to buy 33.38% of the paid-up equity share capital of Unichem Laboratories for INR1,034.06 crore ($160m). The a...

Ipca Laboratories, a pharma company, is a potential buy as it has recorded a breakout from a falling trendline resistance and a Cup & Handl...

EBITDA before forex declined 15% to Rs 262.82 crore in the third quarter of 2022 from Rs 310.83 crore posted in the same quarter of FY22. E...

The scrip has been a favourite of mutual funds and FPIs, who owned over 40 per cent stake in the drug maker, with promoters holding another...

Consolidated total income of the company stood at Rs 1,586.81 crore for the quarter under consideration.

The acquisition of the shares is for cash consideration of Rs 21.20 crore for 5,30,000 equity shares of TWPL, Ipca Labs added.

Its consolidated total income stood at Rs 1,425.21 crore for the quarter under consideration. It was Rs 1,230.99 crore for in the year-ago ...

'Buy Ipca Labs Ltd with a target of Rs 700 and a stop loss of Rs 670'

Ipca Labs is a 'BUY' call with a target of Rs 820 and a stop loss of Rs 640.

Ipca labs is a 'BUY' call with a target of Rs 1,100 and a stop loss of Rs 770.

Ipca Lab is going up and can climb to levels closer to 681 plus zones stop below 654.

Buy IPCA Labs Ltd at a stop of Rs 421.

Buy IPCA Lab Ltd at a stop of Rs 580.